There were 1,138 press releases posted in the last 24 hours and 428,791 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Neos Therapeutics Submits NDA for Amphetamine Extended-Release Liquid Suspension Drug Candidate, NT-0201, for the Treatment of ADHD

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image